Risk of clinical deterioration in patients with lupus nephritis receiving rituximab

Lupus

Volumn 25, Issue 12, 2016, Pages 1299-1306

  Manou Stathopoulou, S ^a   Robson, Michael G ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Lupus; nephritis; rituximab

Indexed keywords

ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CREATININE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; RITUXIMAB; STEROID; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CASE STUDY; CHEST INFECTION; CLINICAL ARTICLE; CLINICAL OUTCOME; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; HEMODIALYSIS; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPERTENSION; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SYNOVITIS; TREATMENT RESPONSE; URINALYSIS; YOUNG ADULT; ADOLESCENT; KIDNEY FUNCTION TEST; LUPUS NEPHRITIS; MALE; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; LUPUS NEPHRITIS; MALE; RETROSPECTIVE STUDIES; RITUXIMAB; STEROIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84988723561     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203316641768     Document Type: Article

References (20)

1. Croca SC, Rodrigues T, Isenberg DA,. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology 2011; 50: 1424-1430.
2. Costenbader KH, Desai A, Alarcón GS, et al. Trends in the incidence, demographics and outcome of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum 2011; 63: 1681-1688.
3. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment and management of lupus nephritis. Arthritis Care Res 2012; 64: 797-808.
4. Kidney Disease Improving Global Outcome. Clinical Practice guideline for glomerulonephritis. Kidney Int Suppl 2012; 2: 221-232.
5. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-2466.
6. Lipsky PE,. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001; 2: 764-766.
7. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus. A Phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589.
8. Díaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European Cohorts. Autoimmun Rev 2012; 11: 357-364.
9. Jónsdóttir T, Zickert A, Sundelin B, et al. Long-term follow up in lupus nephritis patients treated with rituximab-clinical and histopathological response. Rheumatology 2013; 52: 847-855.
10. Davies RJ, Sangle SR, Jordan NP, et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescenteric lupus nephritis. Lupus 2013; 22: 574-582.
11. Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013; 72: 1280-1286.
12. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233.
13. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215-1226.
14. Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. Ann Rheum Dis 2008; 67: 1724-1731.
15. Pepper R, Griffith M, Kirwan C, et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009; 24: 3717-3723.
16. Ezeonyeji AN, Isenberg DA,. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology 2012; 51: 476-481.
17. Melander C, Sallée M, Trolliet P, et al. Rituximab in severe lupus nephritis: Early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009; 4: 579-587.
18. Dias SS, Rodriguez-Garcia V, Nguyen H, et al. Longer duration of B cell depletion is associated with better outcome. Rheumatology 2015; 54: 1876-1881.
19. D'Arcy CA, Mannik M,. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 2001; 44: 1717-1718.
20. Pijpe J, van Imhoff GW, Spijkervet FKL, et al. Rituximab treatment in patients with primary Sjögren's syndrome: An open-label phase II study. Arthritis Rheum 2005; 52: 2740-2750.